retatrutide approval timeline New Weight Loss Drug Retatrutide: My Patient's 85-Pound Journey (And What the Trials Don't Tell You) I personally know plenty of

Nevertheless, future studies should define some aspects: The efficacy and safety of incretin-based therapies

Currently, no large-scale clinical trials have directly examined the relationship between GLP-1 agonists and acne, and these medications are not licensed for dermatological indications

Details are given in the Supplementary material

Diabetologia 46 , 13831393, (2003)

When I mentioned this to Dr

When labs are ordered in GLP-1 treatment, providers typically look at markers that help evaluate metabolic function, organ health, and potential risk factors: A1C and fasting glucose: to assess baseline glycemic control [2] Kidney function: to monitor dehydration risk and fluid balance, which GLP-1-related gastrointestinal side effects can affect [3] Liver enzymes: to ensure safe medication clearance and dosing [4] Lipid panel: to track key cardiometabolic markers that often shift with weight loss [5] Thyroid panel: to rule out thyroid disorders that can contribute to weight changes or mimic weight-related symptoms [6] Complete blood count and electrolytes: to check for underlying health issues or imbalances that could complicate early treatment [7] Important: Because Peak Wellness relies primarily on intake-based evaluation, patients with known medical conditions or incomplete health histories may want to discuss whether additional testing would be beneficial before starting treatment